Vasoactive Intestinal Peptide Immunoregulatory Role at the Periapex: Associative and Mechanistic Evidences from Human and Experimental Periapical Lesions

IntroductionThe balance between the host proinflammatory immune response and the counteracting anti-inflammatory and reparative responses supposedly determine the outcome of periapical lesions. In this scenario, the vasoactive intestinal peptide (VIP) may exert a protective role because of its prominent immunoregulatory capacity. In this study, we investigated (in a cause-and-effect manner) the potential involvement of VIP in the development of human and experimental periapical lesions.MethodsPeriapical granulomas (n = 124) and control samples (n = 48) were comparatively assessed for VIP and multiple immunologic/activity marker expression through real-time polymerase chain reaction. Experimental periapical lesions (C57Bl/6 wild-type mice) were evaluated regarding endogenous VIP expression correlation with lesion development and the effect of recombinant VIP therapy in lesion outcome. CCR4KO and IL4KO strains and anti-glucocorticoid-induced TNFR-related protein inhibition were used to test the involvement of Treg and Th2 cells in VIP-mediated effects.ResultsVIP expression was more prevalent in periapical granulomas than in controls, presenting a positive association with immunoregulatory factors and an inverse association/correlation with proinflammatory mediators and the receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio. Endogenous VIP expression up-regulation was temporally associated with lesion immunoregulation and a decline of bone loss. VIP therapy in mice prompted the arrest of lesion development, being associated with an anti-inflammatory and proreparative response that limits the proinflammatory, Th1, Th17, and osteoclastogenic response in the periapex. The VIP protective effect was dependent of Treg migration and activity and independent of interleukin 4.ConclusionsOur results show that VIP overexpression in human and experimental periapical lesions is associated with lesion inactivity and that VIP therapy results in the attenuation of experimental lesion progression associated with the immunosuppressive response involving Treg cells.     

Evidence of impaired pain modulation in adolescents with idiopathic scoliosis and chronic back pain

BACKGROUND CONTEXT

Although 40% of adolescent idiopathic scoliosis (AIS) patients present with chronic back pain, the pathophysiology and underlying pain mechanisms remain poorly understood. We hypothesized that development of chronic pain syndrome in AIS is associated with alterations in pain modulatory mechanisms.

海水浸泡爆炸伤延期植皮最佳时机的研究

目的确定海水浸泡爆炸伤延期植皮的最佳时机。方法建立海水浸泡爆炸伤动物模型后，分别于0、3、7、14d切取创面组织作病理切片，镜下观察创面受床的病理改变；同期对创区实施植皮术，通过计算机全自动图像分析系统准确计算出各组的皮片成活率。结果分别于伤后0、3、7、14d，对皮肤缺损区施行植皮术，发现不同时机植皮成活率不同，伤后7d对海水浸泡爆炸伤皮肤缺损区植皮，皮片成活率最高。结论海水浸泡爆炸伤延期7d后植皮是对创面实施植皮术的最佳时机。     

凯时治疗慢性重型肝炎患者疗效观察

目的探讨凯时即前列地尔脂微球载体制剂（Lipo-PGE1）治疗慢性重型肝炎的疗效。方法将84例慢性重型肝炎患者随机分成两组，对照组予综合治疗及对症治疗，治疗组在该基础上加用凯时10μg溶于5％葡萄糖注射液250ml中静脉缓慢滴注，1次/d，疗程为4周。结果治疗组对慢性重型肝炎的疗效优于对照组（P〈0．01），肝功能改善优于对照组（P〈0．01）。结论Lipo-PCEI是一种治疗慢性重型肝炎安全、有效的药物。     

补肾排毒合剂治疗慢性肾衰竭营养不良60例临床观察

目的:观察补肾排毒合剂治疗慢性肾衰竭营养不良的疗效.方法:90例慢性肾衰竭营养不良患者随机分为治疗组60例和对照组30例,并设健康对照组30例.治疗组和对照组在综合治疗的基础上,治疗组加用补肾排毒合剂,对照组加用爱西特和百令胶囊.比较两组肾功能、营养状态和血浆瘦素、神经肽Y的变化.结果:治疗组治疗后BUN、Scr明显降低,与治疗前及对照组相比均有统计学差异(P<0.05).治疗组营养状态好转,与治疗前及对照组相比均有统计学差异(P<0.05).两组慢性肾衰竭营养不良患者治疗前Leptin、NPY水平均高于健康组(P<0.05),治疗后治疗组Leptin、NPY较治疗前下降,有统计学意义(P<0.05),但与对照组相比无统计学差异(P＞0.05).结论:补肾排毒合剂治疗慢性肾衰竭营养不良疗效明显,可降低BUN、Scr,改善营养不良状态.     

皮瓣展平法在耳廓再造时扩张皮瓣感染中的应用

目的探索耳廓再造时扩张皮瓣感染的处理方法。方法分析中国协和医科大学整形外科医院外耳冉造中心2003年1月～2005年12月耳廓再造时耳后扩张皮瓣发生感染，经皮瓣展平法处理，感染控制后进行耳再造的12例（12耳）患者的治疗情况。结果12例（12耳）患者手术顺利，术后恢复好，再造耳效果与无感染者无明显差异。结论皮瓣展平法是耳廓再造时扩张皮瓣感染较理想的处理方法。     

动脉瘤性蛛网膜下腔出血后慢性脑积水

目的探讨动脉瘤性蛛网膜下腔出血后(aSAH)慢性脑积水的发生率及其易患因素。方法回顾性研究2003年1月至2005年9月我科aSAH病例221例,采用单因素及多因素统计方法分析与慢性脑积水发生的相关影响因素。结果慢性脑积水的发生率为12.7%(28/221)。经单因素分析显示,患者年龄、Hunt-Hess级别、Fisher级别、前交通动脉瘤、aSAH次数以及脑室内出血具有统计学意义;多因素logistic回归分析显示,Fisher级别、脑室内出血、aSAH次数、前交通动脉瘤具有统计学意义。结论慢性脑积水为aSAH后一较常见并发症,影响其发生的高危因素包括Fisher级别、脑室内出血、aSAH次数、前交通动脉瘤。对具上述危险因素的aSAH患者应注意跟踪随访,及时诊治。